基于模拟的评估实证阿米卡辛的剂量在高风险的成年人发烧性中和血液恶性瘤使用人口药理动力学建模的高风险的阿米卡辛
Jared Tun Fang Loo1, Guan Chin Leong1,2, Siti Maisharah Sheikh Ghadzi1
1School of Pharmaceutical Sciences, Universiti Sains Malaysia, Penang, Malaysia.
Therapeutic drug monitoring
|December 30, 2025
概括
高危癌症患者可能需要调整阿米卡辛的剂量. 基于功能和白蛋白的个性化策略对于优化这种抗生素至关重要.
科学领域:
- 药理学 药理学是指药理学的学科.
- 在瘤学瘤学.
- 腎臟病學 (nephrology) 是一種醫學專業.
背景情况:
- 接受化疗的癌症患者通常需要更高的初始阿米卡辛剂量.
- 个性化剂量策略和治疗药物监测对于优化阿米卡辛的有效性和安全性至关重要.
- 患有中性衰竭和血液性恶性瘤的高风险成年人需要量身定制的阿米卡给药.
研究的目的:
- 在高风险成年人中开发实证阿米卡辛的种群药动力学模型.
- 用蒙特卡洛模拟来评估当前的剂量方案是否达到治疗目标.
- 在这个患者群体中确定影响阿米卡辛药理学的关键共变量.
主要方法:
- 在83名患有血液学疾病的患者中,使用NONMEM开发了一种单间人群的药理动力学模型.
- 评估了包括功能估计,体型和实验室参数在内的临床共变量.
- 蒙特卡洛模拟评估了四种每日一次的阿米卡辛剂量方案 (15-30 mg/kg).
主要成果:
- 专蛋白,体型和体重调整后的肌素清除被确定为影响阿米卡辛药理学的关键共变量.
- 模拟表明,标准的15mg/kg阿米卡辛剂量可能对某些患者亚组来说是次优的.
- 阿米卡辛暴露受到功能和血清白蛋白水平的显著影响.
结论:
- 基于模型的剂量策略可能是优化实证阿米卡辛治疗的必要条件.
- 功能和血清白蛋白是影响高风险患者阿米卡辛暴露的关键因素.
- 优化阿米卡辛治疗需要考虑个体患者的特征,如功能和白蛋白水平.
相关概念视频
01:20Estimation of k and VD of Aminoglycosides
191
Aminoglycosides are a class of antibiotics used to treat various bacterial infections. Clinicians must determine the elimination rate constant (k) and volume of distribution (VD) to optimize therapeutic efficacy and minimize toxicity. The k value represents the rate at which the drug is removed from the body, and the VD reflects the degree to which the drug distributes into body tissues. Accurately estimating these parameters allows healthcare professionals to tailor drug dosing to individual...
191
01:15Determination of Multiple Dosing Parameters: Steady-State, Minimum and Maximum Concentrations
209
Gentamicin, an aminoglycoside antibiotic, is commonly administered via intermittent intravenous infusion to treat severe infections. An intermittent one-hour infusion of gentamicin, administered at eight-hour intervals, allows for precise control of plasma drug concentrations, minimizing toxicity while ensuring therapeutic efficacy. Pharmacokinetic principles govern the dynamics of plasma concentrations and can be mathematically described using specific equations.The plasma drug concentration...
209
01:12Analysis of Population Pharmacokinetic Data
648
Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
648
01:01Dosage Regimens: Partial Pharmacokinetic Parameters
133
It is not uncommon for complete drug pharmacokinetic profiles to remain elusive in pharmacokinetics. This necessitates certain educated assumptions by pharmacokineticists to determine appropriate dosage regimens without comprehensive pharmacokinetic data from animal or human studies. One prevalent assumption is setting the bioavailability factor, denoted as F, to 1 or 100%. This assumption caters to the scenario where a drug doesn't achieve full systemic absorption, resulting in the patient...
133
00:59Model-Independent Approaches for Pharmacokinetic Data: Noncompartmental Analysis
290
Noncompartmental analyses offer an alternative method for describing drug pharmacokinetics without relying on a specific compartmental model. In this approach, the drug's pharmacokinetics are assumed to be linear, with the terminal phase log-linear. This assumption allows for simplified analysis and interpretation of the drug's behavior in the body.
One important characteristic of noncompartmental analyses is that drug exposure increases proportionally with increasing doses. This...
One important characteristic of noncompartmental analyses is that drug exposure increases proportionally with increasing doses. This...
290
01:26Pharmacokinetics in Pediatric Patients: Drug Excretion
191
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
191